Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lixisenatide cardiovascular outcomes study after acute coronary syndrome in type 2 diabetes
NL-OMON39895Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jan 2011
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Lixisenatide with Placebo (2 arms). Primary endpoint: Major adverse cardiovascular event composite. Started Jan 2011; status: active, not recruiting.
02
Drugs
lixisenatide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON39895.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39895.